A third of pharmaceutical companies miss Q2 average estimate

Almost one-third of the BSE 100 pharmaceutical companies have missed the average estimate in the quarter ended September 2018, pulled down by the lower sales and anti-trust litigation provision.

A third of pharmaceutical companies miss Q2 average
Almost one-third of the BSE 100 pharmaceutical companies have missed the average estimate in the quarter ended September 2018. Image source: DNA

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x